SCHEMBL5565932

SCHEMBL5565932

COc1cc2c(Oc3cc(-c4ccccc4)[nH]n3)ncnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 13/20 0.60
▸ FLT4 P35916 10/20 0.60
▸ TEK Q02763 8/20 0.60
▸ AURKB Q96GD4 8/20 0.60
▸ PDGFRB P09619 7/20 0.60
▸ AURKA O14965 7/20 0.60
▸ EGFR P00533 8/20 0.53
▸ KIT P10721 3/20 0.53
▸ FLT1 P17948 5/20 0.51
▸ ERBB2 P04626 3/20 0.51
▸ FGFR1 P11362 3/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ GAK O14976 1/20 0.51
▸ EPHB6 O15197 1/20 0.51
▸ RIPK2 O43353 1/20 0.51
▸ ERN1 O75460 1/20 0.51
▸ STK10 O94804 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ CHEK2 O96017 1/20 0.51
▸ ABL1 P00519 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7885709 0.94 KDR (0.53) KDRFLT4TEKAURKBPDGFRB
SCHEMBL5565918 0.93 SRC (0.57) KDRFLT4TEKAURKBPDGFRB
SCHEMBL5566618 0.92 KDR (0.61) KDRFLT4TEKAURKBPDGFRB
Hydrochloric Acid SCHEMBL5566627 0.92 SRC (0.56) KDRFLT4TEKAURKBPDGFRB
SCHEMBL5565868 0.86 KDM1A (0.56) KDRFLT4PDGFRBEGFRFLT1
SCHEMBL5566781 0.85 EGFR (0.50) KDRFLT4PDGFRBEGFRLCK
SCHEMBL5560704 0.85 KDM1A (0.55) KDRFLT4TEKAURKBPDGFRB
Hydrochloric Acid SCHEMBL5566986 0.85 KDM1A (0.55) KDRFLT4PDGFRBEGFRFLT1
SCHEMBL19258107 0.85 KDR (0.73) KDRFLT4TEKAURKBPDGFRB
SCHEMBL5561051 0.85 FLT4 (0.52) KDRFLT4TEKAURKBPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 — — EP claimed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP claimed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed
Send feedback